Xiaoxiao Sun

5 Questions 8 Answers 0 Followers

Questions related from Xiaoxiao Sun

RNAseq data from cancer biopsies during treatment or post-neoadjuvant treatment, and with longitudinal clinical outcomes?

We want to study prognostic features in our specific domain of interest. Particularly, we want to look at transcriptomics of cancers during treatment or without subsequent treatment, and their...

10 April 2020 2,729 0 View

What is the standard care for NSCLC patient who relapse from EGFRi but w/o T790M?

Does anybody know in current clinical practice, what is the therapeutic option for EGFR mutation NSCLC patients who develop acquired resistance to first-line EGFR inhibitor but do not have T790M...

29 July 2017 1,328 5 View

Do KRAS mutant cells completely bypass upstream receptor tyrosine kinases?

It is generally accepted that KRAS mutations shortcut the signal transductions which physiologically tranfer extracellular signals into nucleus. The mutated KRAS forms a blocking configuration...

03 November 2014 4,307 5 View

Why is there no c-Met inhibitor available in clinic?

C-Met is validated for its oncogenic function for long time. And its gene amplification is seen in several kinds of cancers (lung, gastric). However, there is still no Met inhibitor available in...

11 April 2014 3,343 9 View

How to separate tumor cells from primary tumor samples?

I am planning on creating tumor cell lines from clinical patient tumor samples. However, fibroblasts proliferate very quickly in vitro, making it difficult to separate pure tumor cells. Does...

10 April 2014 5,449 21 View